ANIP Q1 2017 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$37M+78.2% YoY

Gross Profit

$20M55.3% margin

Operating Income

$5M12.6% margin

Net Income

$1M3.1% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

-4.1%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

-$47M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$357M

Total Liabilities

$185M

Stockholders' Equity

$172M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$21M	+78.2%
Gross Profit	$20M	$17M	+18.1%
Operating Income	$5M	$6M	-18.4%
Net Income	$1M	$1M	-14.8%

Revenue Segments

Unapproved Products

$6M100%